Navigation Links
Lilly Reports Fourth-Quarter and Full-Year 2009 Results
Date:1/28/2010

his 14 percent revenue growth was comprised of an increase of 7 percent due to higher volume, 3 percent due to higher prices, and 3 percent due to the impact of foreign exchange rates (numbers do not add due to rounding). Total revenue in the U.S. increased 11 percent to $3.261 billion due to higher prices and wholesaler buying patterns. Total revenue outside the U.S. increased 18 percent to $2.673 billion due to increased demand and the positive impact of foreign exchange rates, partially offset by lower prices.

Gross margin as a percent of total revenue decreased by 6.6 percentage points, to 75.9 percent. Cost of sales increased by 57 percent in the fourth quarter of 2009 compared to the fourth quarter of 2008. The decrease in gross margin was due to the impact of changes in foreign currencies compared to the U.S. dollar on international inventories sold during the quarter, which substantially increased cost of sales in the fourth quarter of 2009, but substantially decreased cost of sales in the fourth quarter of 2008.

Marketing, selling and administrative expenses increased 13 percent compared with the fourth quarter of 2008, to $1.953 billion. The increase was driven by higher marketing and selling expenses outside the U.S. and the impact of foreign exchange rates. Research and development expenses were $1.217 billion, or 21 percent of total revenue. Compared with the fourth quarter of 2008, research and development expenses grew 15 percent due primarily to the ImClone acquisition, increased incentive compensation and increased late-stage clinical trial costs.  Total operating expenses, defined as the sum of research and development, marketing, selling and administrative expenses, increased 14 percent compared with the fourth quarter of 2008.

In the fourth quarters of 2009 and 2008, the company recog
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... study published in the Proceedings of the ... that showed when ibrutinib (IMBRUVICA ® ) was ... suppression of tumor growth was enhanced suggesting a ... hematologic cancers and solid tumors with the combination. ...
(Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... forma net operating loss (NOL) guidance and its cash ...  Isis, significantly improved financial results were due in large ... the Company received from its partners.  Isis, pro forma ... 60% improvement over its 2013 NOL of $40.2 million. ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... 2, 2011 Men who take non-steroidal anti-inflammatory drugs three ... times more likely to have erectile dysfunction compared to men ... Kaiser Permanente study published online in The Journal of ... trend toward this same finding, this observational study used electronic ...
... SILVER SPRING, Md., March 2, 2011 The U.S. ... that manufacture, distribute, or market certain unapproved prescription oral ... be legally marketed in the United States. ... cough, cold, and allergy drug products have not been ...
Cached Medicine Technology:Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 2Non-Steroidal Anti-Inflammatory Drugs Linked to Increased Risk of Erectile Dysfunction 3FDA Prompts Removal of Unapproved Drugs From Market 2FDA Prompts Removal of Unapproved Drugs From Market 3
(Date:2/28/2015)... February 28, 2015 March—also known ... time to remind ourselves and others that suspected ... Atlantic NeuroSurgical Specialists (ANS). , Concussions are a ... for 75% of TBIs. There are 1.6-3.8 million ... sound benign, but it is a brain injury. ...
(Date:2/28/2015)... 2015 Indosoft Inc , developers ... Asterisk, are pleased to announce the development of Q-Suite ... 5.8 versions of Q-Suite, this new version will include ... of new features to the leading edge call center ... 5.9 will add features to enhance security and protection. ...
(Date:2/28/2015)... 2015 The Mesothelioma Applied Research ... at the International Symposium on Malignant Mesothelioma on Monday, ... the Hyatt Regency Bethesda in Bethesda, Maryland. The following ... and commitment to the mission to cure mesothelioma. , ... be presented to Miriam Ratner. Miriam runs the Meso ...
(Date:2/28/2015)... February 28, 2015 Dr. Perry ... Coast area residents, recently announced a special offer for ... a treatment option for new and established patients at ... with a bright, white smile, Dr. Patel and his ... $299, marked down from the regular price of $450. ...
(Date:2/28/2015)... 2015 Kaylie Corrigan, Outdoor Supervisor at ... , and current student obtaining her Masters degree in ... weekly forum in psychoeducation on substance use for teens ... as part of her studies. , “Even though these ... and counseling at the high school and junior high ...
Breaking Medicine News(10 mins):Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... ... informs consumers how to dispute inaccuracies in their credit file , ... Delray Beach, FL (PRWEB) February 9, ... today announced the importance of ensuring a clean credit report and reminds consumers of ...
... should consider preventive measures, study suggests , TUESDAY, Feb. 9 ... much more likely to develop blood clots than people without ... make preventive drug treatment necessary, it adds. , The study, ... who had inflammatory bowel disease (IBD) with 71,672 people who ...
... ... Exploration Summer Programs , open to students around the world, is offering ... 6 to 9, providing an in-depth experience in the culinary arts, emergency ... Exploration Focus Programs will give kids an opportunity to spend ...
... , ... Heart Association’s Go Red For Women® Movement to Fight Heart Disease in Eastern Washington ... Eastern Washington ... Walla Walla, Clarkston, Hermiston, OR, Lewiston, ID announce their participation in year three of ...
... Mich. , Feb. 9 People with depression ... even when they are treated with antidepressants, according to a ... Environmental Medicine. , The study, led by researchers from ... data for more than 22,000 patients diagnosed with depression and ...
... ... applications in iTunes, Healthcare & Fitness category , ... San Francisco (PRWEB) February 9, 2010 -- Abvio demonstrates the ... and Walkmeter , at Macworld 2010 . All three are among the top ...
Cached Medicine News:Health News:NationalCreditReport.com Reminds Consumers of Ways to Improve Credit Report and Score in 2010 2Health News:Inflammatory Bowel Ups Risk for Blood Clots 2Health News:Time to 'Get Focused' at Exploration Summer Programs 2Health News:Time to 'Get Focused' at Exploration Summer Programs 3Health News:Time to 'Get Focused' at Exploration Summer Programs 4Health News: Eastern Washington Jiffy Lube Service Centers Embark on Year Three of Successful Maintenance Partners For Life Campaign 2Health News: Eastern Washington Jiffy Lube Service Centers Embark on Year Three of Successful Maintenance Partners For Life Campaign 3Health News: Eastern Washington Jiffy Lube Service Centers Embark on Year Three of Successful Maintenance Partners For Life Campaign 4Health News:Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study 2Health News:Media Alert: Abvio Demonstrates Innovative iPhone 3G/3GS Fitness Applications for Running, Cycling and Walking at Macworld 2010 2
EC+ Extra Care Bariatric Bed...
... feature folding head end and foot end deck panels ... end and foot end deck panels folded the overall ... This compact length makes storage, delivery and pick up ... not available on Model 4748B, Basic Maxi Rest bariatric ...
... I system is a unique ... combines dual width capability with ... roll" design. Specifically developed to ... patients, the easy-to-use Tri-Flex I ...
... system is a unique healthcare ... dual width capability with a ... design. Specifically developed to accommodate ... the easy-to-use Tri-Flex I system ...
Medicine Products: